cefixime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	537	79350-37-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefixime cefixim cefiximine cefixoral	A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases. Molecular weight: 453.44 Formula: C16H15N5O7S2 CLOGP: -0.17 LIPINSKI: 1 HAC: 12 HDO: 4 TPSA: 184.51 ALOGS: -3.64 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefixime
cefixim
cefiximine
cefixoral

A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.

Molecular weight: 453.44
Formula: C16H15N5O7S2
CLOGP: -0.17
LIPINSKI: 1
HAC: 12
HDO: 4
TPSA: 184.51
ALOGS: -3.64
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.06 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	41 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	29.33 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	47 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.24 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.31 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
April 28, 1989	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	63.75	20.26	80	3229	250930	50350885
Gastroenteritis staphylococcal	43.67	20.26	7	3302	70	50601745
Secretion discharge	32.98	20.26	15	3294	9776	50592039
Panic attack	31.11	20.26	18	3291	19324	50582491
Mucocutaneous candidiasis	30.15	20.26	4	3305	8	50601807
Pulmonary congestion	29.44	20.26	16	3293	15231	50586584
Dysbiosis	28.67	20.26	7	3302	653	50601162
Biopsy colon abnormal	27.55	20.26	5	3304	109	50601706
Gastrointestinal mucosa hyperaemia	25.06	20.26	5	3304	183	50601632
Movement disorder	24.67	20.26	15	3294	17617	50584198
Oligohydramnios	23.20	20.26	10	3299	5740	50596075
Vaginal infection	22.42	20.26	10	3299	6226	50595589
Malignant melanoma in situ	22.33	20.26	6	3303	819	50600996
Candida test positive	22.05	20.26	6	3303	858	50600957
Foetal growth restriction	21.84	20.26	10	3299	6617	50595198
Premature baby	21.63	20.26	14	3295	18323	50583492
Pulmonary mass	21.38	20.26	14	3295	18691	50583124
Disorientation	21.23	20.26	18	3291	35466	50566349
Drug reaction with eosinophilia and systemic symptoms	20.33	20.26	16	3293	28408	50573407

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Oral pustule	43.95	24.91	8	1425	243	29572851
Psoriatic arthropathy	37.75	24.91	17	1416	14674	29558420

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Secretion discharge	54.52	18.90	23	4406	11941	64482362
Panic attack	50.76	18.90	26	4403	20927	64473376
Drug hypersensitivity	48.54	18.90	70	4359	237745	64256558
Pulmonary congestion	44.81	18.90	25	4404	23855	64470448
Psoriatic arthropathy	44.75	18.90	31	4398	43250	64451053
Movement disorder	41.19	18.90	23	4406	21977	64472326
Oral pustule	40.33	18.90	8	4421	270	64494033
Pulmonary mass	39.31	18.90	23	4406	23993	64470310
Clostridium difficile colitis	39.18	18.90	24	4405	27199	64467104
Gastroenteritis staphylococcal	34.31	18.90	7	4422	273	64494030
Dysbiosis	31.02	18.90	8	4421	887	64493416
Biopsy colon abnormal	27.91	18.90	5	4424	96	64494207
Agranulocytosis	25.33	18.90	21	4408	38208	64456095
Mucocutaneous candidiasis	24.76	18.90	4	4425	40	64494263
Acute generalised exanthematous pustulosis	24.43	18.90	14	4415	14044	64480259
Pseudomembranous colitis	24.23	18.90	10	4419	4906	64489397
Vaginal infection	24.23	18.90	10	4419	4910	64489393
Drug reaction with eosinophilia and systemic symptoms	22.65	18.90	23	4406	54194	64440109
Gastrointestinal mucosa hyperaemia	20.76	18.90	5	4424	419	64493884
Candida test positive	20.49	18.90	6	4423	1064	64493239
Psoriasis	18.98	18.90	24	4405	71679	64422624

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DD08	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
ATC	J01RA15	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:88188	allergenic drug
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute otitis media	indication	3110003
Gonorrhea	indication	15628003	DOID:7551
Acute gonococcal cervicitis	indication	20943002	DOID:10615
Acute gonococcal urethritis	indication	29864006
Bronchitis	indication	32398004	DOID:6132
Streptococcal tonsillitis	indication	41582007
Upper respiratory infection	indication	54150009
Urinary tract infectious disease	indication	68566005
Tonsillitis	indication	90176007	DOID:10456
Acute bacterial bronchitis	indication	233598009
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Streptococcus pyogenes infection	indication	302809008
Infective otitis media	indication	312218008
Pharyngitis	indication	405737000	DOID:2275
Acute exacerbation of chronic bronchitis	indication	425748003
Haemophilus Influenzae Acute Otitis Media	indication
Haemophilus Influenzae Chronic Bronchitis	indication
Streptococcus Pneumoniae Chronic Bronchitis	indication
Haemophilus Influenzae Bronchitis	indication
Moraxella Catarrhalis Acute Otitis Media	indication
Streptococcus Pneumoniae Bronchitis	indication
Pneumonia due to Escherichia coli	off-label use	51530003
Acute bacterial sinusitis	off-label use	75498004
Haemophilus Parahaemolyticus Pneumonia	off-label use
Haemophilus Parainfluenzae Pneumonia	off-label use
Impaired renal function disorder	contraindication	197663003
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.45	acidic
pKa2	2.54	acidic
pKa3	3.24	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
500MG/5ML	SUPRAX	LUPIN LTD	N202091	Feb. 20, 2013	RX	FOR SUSPENSION	ORAL	9233112	Dec. 14, 2028	METHODS FOR TREATING BACTERIAL INFECTIONS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		IC50	4.24	WOMBAT-PK
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1	Enzyme	P19174	PLCG1_HUMAN		IC50	5.92	CHEMBL
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR			CHEMBL	CHEMBL
Streptokinase A	Enzyme		STRP_STRP1		EC50	7.22	WOMBAT-PK

External reference:

ID	Source
4019391	VUID
N0000147544	NUI
D00258	KEGG_DRUG
25033	RXNORM
4019391	VANDF
C0060400	UMLSCUI
CHEBI:472657	CHEBI
C04	PDB_CHEM_ID
CHEMBL1541	ChEMBL_ID
D020682	MESH_DESCRIPTOR_UI
DB00671	DRUGBANK_ID
10898	IUPHAR_LIGAND_ID
97I1C92E55	UNII
5362065	PUBCHEM_CID
233747	MMSL
4374	MMSL
d00072	MMSL
002737	NDDF
387536009	SNOMEDCT_US
96052006	SNOMEDCT_US
125110-14-7	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	16714-766	POWDER, FOR SUSPENSION	100 mg	ORAL	ANDA	27 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	16714-767	POWDER, FOR SUSPENSION	200 mg	ORAL	ANDA	27 sections
SUPRAX	HUMAN PRESCRIPTION DRUG LABEL	1	27437-201	TABLET	400 mg	ORAL	ANDA	27 sections
SUPRAX	HUMAN PRESCRIPTION DRUG LABEL	1	27437-203	TABLET, CHEWABLE	100 mg	ORAL	ANDA	19 sections
SUPRAX	HUMAN PRESCRIPTION DRUG LABEL	1	27437-203	TABLET, CHEWABLE	100 mg	ORAL	ANDA	19 sections
SUPRAX	HUMAN PRESCRIPTION DRUG LABEL	1	27437-205	TABLET, CHEWABLE	200 mg	ORAL	ANDA	19 sections
SUPRAX	HUMAN PRESCRIPTION DRUG LABEL	1	27437-205	TABLET, CHEWABLE	200 mg	ORAL	ANDA	19 sections
SUPRAX	HUMAN PRESCRIPTION DRUG LABEL	1	27437-206	POWDER, FOR SUSPENSION	200 mg	ORAL	ANDA	27 sections
SUPRAX	HUMAN PRESCRIPTION DRUG LABEL	1	27437-207	POWDER, FOR SUSPENSION	500 mg	ORAL	NDA	27 sections
SUPRAX	HUMAN PRESCRIPTION DRUG LABEL	1	27437-208	CAPSULE	400 mg	ORAL	NDA	27 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	43598-673	POWDER, FOR SUSPENSION	100 mg	ORAL	ANDA	22 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	43598-674	POWDER, FOR SUSPENSION	200 mg	ORAL	ANDA	22 sections
SUPRAX	HUMAN PRESCRIPTION DRUG LABEL	1	54348-797	CAPSULE	400 mg	ORAL	ANDA	27 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	62250-663	POWDER, FOR SUSPENSION	100 mg	ORAL	ANDA	27 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	62250-664	POWDER, FOR SUSPENSION	200 mg	ORAL	ANDA	27 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	62250-668	POWDER, FOR SUSPENSION	500 mg	ORAL	ANDA	27 sections
Cefixime	Human Prescription Drug Label	1	65862-751	POWDER, FOR SUSPENSION	100 mg	ORAL	ANDA	25 sections
Cefixime	Human Prescription Drug Label	1	65862-752	POWDER, FOR SUSPENSION	200 mg	ORAL	ANDA	25 sections
CEFIXIME	Human Prescription Drug Label	1	67877-584	CAPSULE	400 mg	ORAL	ANDA	24 sections
CEFIXIME	Human Prescription Drug Label	1	67877-584	CAPSULE	400 mg	ORAL	ANDA	24 sections
SUPRAX	HUMAN PRESCRIPTION DRUG LABEL	1	68180-202	POWDER, FOR SUSPENSION	100 mg	ORAL	ANDA	27 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	68180-405	POWDER, FOR SUSPENSION	100 mg	ORAL	ANDA	25 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	68180-407	POWDER, FOR SUSPENSION	200 mg	ORAL	ANDA	25 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	68180-416	CAPSULE	400 mg	ORAL	ANDA	25 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	68180-423	CAPSULE	400 mg	ORAL	NDA authorized generic	25 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2749	CAPSULE	400 mg	ORAL	ANDA	24 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	70518-3221	CAPSULE	400 mg	ORAL	NDA authorized generic	25 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	70518-3221	CAPSULE	400 mg	ORAL	NDA authorized generic	25 sections
SUPRAX	HUMAN PRESCRIPTION DRUG LABEL	1	70934-079	CAPSULE	400 mg	ORAL	NDA	28 sections